Clinical trials: Major Depression
Major Depressive Disorder
Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression
The purpose of this research study is to find out if a test can predict whether someone with depression will get better with treatment.
- Trial name
- NCT00824044
- Testing
- Cognitive Behavioral Therapy (CBT), Escitalopram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study of LY2216684 and Theophylline in Healthy Subjects
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme.
- Trial name
- NCT01263106
- Testing
- LY2216684, Theophylline
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Ketamine in the Treatment of Depression
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug.
- Trial name
- NCT01558063
- Testing
- Ketamine, Saline, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Columbia University
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Healthy Controls
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs.
- Trial name
- UNIKET (NCT05046184)
- Testing
- Ketamine Hydrochloride, Midazolam injection
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission
KAP for Depression in Abstinent Opioid Users
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused…
- Conditions
- Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
- Trial name
- KReDO (NCT05193318)
- Testing
- Ketamine-assisted psychotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Major Depressive Disorder
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor…
- Trial name
- NCT05932407
- Testing
- Vortioxetine Tablet, SSRI
- Where
- Japan
- Volunteers
- 147,777 people
- Sponsor
- Takeda
Major Depressive Disorder
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects.
- Trial name
- NCT00952653
- Testing
- Desvenlafaxine Succinate Sustained Release, Midazolam
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depression
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
- Trial name
- NCT00200902
- Testing
- Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Interpersonal Clinical Interaction (ICI)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of California, Los Angeles
Major Depression
Lexapro and Pramipexole and to Treat Major Depression
This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone.
- Trial name
- NCT00086307
- Testing
- Pramipexole, Escitalopram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01072630
- Testing
- Armodafinil
- Where
- 92 sites in United States, Argentina and 8 more
- Volunteers
- 492 people
- Sponsor
- Cephalon
Major Depressive Disorder
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
The purpose of this study is to examine whether neural-derived exosomal miRNAs are differentially expressed that are specific to suicidal ideation or behavior, and which by affecting specific miRNA targets and pathways, are…
- Trial name
- NCT02418195
- Testing
- ketamine
- Where
- United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Stress and the Sympathetic Nervous System in Adults With Depression
To test our hypotheses, we will enroll healthy adults having no history of mood disorders and adults with major depressive disorder (MDD) having a broad range of depressive symptom severity.
- Trial name
- NCT04838262
- Testing
- Acute Stressors
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Mental Disorders, Severe, Schizophrenia and Related Disorders
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
Insufficient community-based support after inpatient discharge for persons with serious mental illnesses (SMI) may lead to re-hospitalization, excessive criminal justice involvement, homelessness, and an inability to embrace…
- Conditions
- Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
- Trial name
- ODR (NCT04612777)
- Testing
- Opening Doors to Recovery, Case Management, Intensive Case Management
- Volunteers
- 240 people
- Sponsor
- New York State Psychiatric Institute